

# Index

- 5HT<sub>2</sub> receptor antagonists  
     *see* serotonin 5HT<sub>2</sub> receptor antagonists  
 5-HT *see* serotonin 5-HT  
 5-HTTLPR *see* serotonin 5-HTTLPR transporter
- abused children, 364  
 acetaminophen, 173  
 acetylcholine, 15–16  
 acetylcholinesterase, 305  
 acetylcholinesterase inhibitor, 169, 333  
     *see also* memantine;  
     rivastigmine  
 actigraphy, 41, 107  
     ADHD, 348, 349, 352, 353  
     autism spectrum disorders, 376  
     circadian rhythm phases, 190–1, 306  
     euthymic bipolar subjects, 272  
     excessive daytime sleepiness, 147  
     in mania, 267, 269  
     insomnia, 206  
     schizophrenia, 306  
     sleep onset latency, 349  
 activation level, AIM model, 3, 6  
 activation-synthesis hypothesis, 4–5  
 active sleep, in infancy, 42  
 activity, pre-sleep *see* sleep habits/hygiene  
 actogram  
     advanced sleep phase disorder, 188  
     delayed sleep phase disorder, 187  
     irregular sleep–wake rhythm, 190  
     non-24-hour sleep–wake syndrome, 189, 191  
 addiction, new research, 389  
 adenosine, 25–6, 252  
 adenotonsillectomy, 347, 351, 378, 379  
 ADHD *see* attention-deficit/hyperactivity disorder (ADHD)  
 adipocyte-derived hormone *see* leptin  
 adolescents, 374  
     anxiety disorders, 287, 288, 292, 365  
     cannabis use, 316  
     circadian rhythm alterations, 187, 362  
     confusional arousal, 162  
     depression, 359–60, 361, 362, 363  
     Kleine-Levin syndrome, 153  
     obsessive-compulsive disorder, 288  
     sleep–wake changes, 42–3  
     slow-wave sleep deficits, 304  
     social phobia, 287  
 adrenocorticotrophic hormone (ACTH), 39  
 adults  
     ADHD, 343  
     dreaming development, 9  
     sleep–wake changes, 43  
 advanced sleep phase disorder (ASPD), 186, 188, 191, 331  
 affective disorders, 138–40, 195  
 aging  
     sleep changes in, 330,  
     *see also* elderly people  
 agomelatine, 392  
 AIM model, 6, 7  
 airway obstruction  
     Down syndrome, 379  
     *see also* obstructive sleep apnea (OSA)  
 alcohol abuse-induced sleep disorders, 43, 314  
     behavioral therapy, 322, 323  
     insomnia, 314, 322, 323, 388  
     nightmare disorder, 164, 169  
     pharmacotherapy, 224, 226, 227, 322, 323  
     relapse risk factors, 316  
     sleepwalking, 164  
 alcohol use  
     obstructive sleep apnea, 122  
     REM sleep behavior disorder, 167  
 alien limb phenomenon, 339  
 almorexant, 392  
 alpha cortical activity, in NREM sleep, 18  
 alpha waves, on EEG, 14–15, 40  
 alpha-1 adrenoreceptor antagonist, 177  
     REM sleep behavior disorder,  
     *see also* prazosin  
 alpha–delta sleep, 154  
 alpha-methyl-paratyrosine (AMPT), 321  
 alprazolam, 217  
 Alzheimer's disease (AD), 332  
     dementia with Lewy bodies, 335  
     obstructive sleep apnea in, 334  
     sleep–wake changes, 43, 196, 331–4  
     treatment, 196, 333–4  
     vascular dementia and, 334  
 amantadine, 169, 338  
 American Academy of Sleep Medicine (AASM), 393  
 American College of Medical Graduates (ACGME), 393  
 aminergic modulatory ratio, 6  
 aminergic system, 3–4, 8  
     in depression, 257  
 amphetamines  
     abuse of, 319, 320, 323  
     effects on sleep, 352  
     for ADHD, 343  
     parasomnias induced by, 169  
 amygdala-medio-prefrontal connectivity, 52  
 amyloid plaques, 332, 333  
 analytical psychology, on dreams, 79, 88  
 anemia *see* iron deficiency  
 Angelman syndrome, 381  
 ANS *see* autonomic nervous system (ANS)  
 anterior hypothalamus, damage, 15  
 antiadrenergic drugs, 155–6  
 antiepileptic agent, 151  
 anticholinergic drugs, 155–6, 223  
 anticonvulsants  
     for insomnia, 226, 277, 322  
     for nightmares, 177  
     side-effects, 226 *see also* gabapentin;  
     lorazepam; pregabalin;  
     tiagabine; topiramate  
 antidepressant therapy, sleep deprivation, 392  
 antidepressants, 44  
     ADHD, 352  
     bipolar disorder, 275  
     cataplexy, 151  
     depression-related insomnia, 222–4, 227, 257–8  
     major depressive disorders, 226–7  
     obstructive sleep apnea, 120, 121  
     parasomnias, 164, 169  
     REM sleep behavior disorder, 169  
     side-effects

## Index

- periodic leg movements of sleep, 140  
 restless legs syndrome, 135–6, 139–40, 275  
 sleep-onset REM period suppression, 147–8  
 substance-related insomnia, 169, 323  
 wake-promoting system blockers, 219  
*see also* doxepin; mirtazapine; selective serotonin reuptake inhibitors (SSRIs); trazodone
- antidopaminergic drugs, 155–6  
 antiepileptic drugs (AEDs), 44  
 obstructive sleep apnea and, 120  
 parasomnias and, 164  
 restless legs syndrome, 138  
*see also* pregabalin; tiagabine; valproic acid
- antihistamines  
 for insomnia, 225–6  
 in ADHD, 352  
 parasomnias and, 164  
 side-effects, 139, 155–6, 225–6, 352  
*see also* cyproheptadine; diphenhydramine; doxylamine; trazodone
- antihypertensive drugs, 156  
 antiparkinsonian drugs  
*see* Parkinson's disease (PD)
- antipsychotics, 46, 308  
 bipolar disorder, 269–70, 275, 277  
 for insomnia, 224–5, 258, 277  
 substance-related, 323  
 in schizophrenia, 307  
 obstructive sleep apnea, 120, 121  
 post-traumatic stress disorder, 293  
 risks in Alzheimer's disease patients, 333  
 side-effects, 225  
*see also* benzodiazepines; benzodiazepine receptor agonists (BzRAs); olanzapine; quetiapine; risperidone; trazodone  
 restless legs syndrome, 135, 275  
 sleep disorders, 345
- anxiety  
 after childhood sleep problems, 365  
 depression and, 117  
 extinction by dreaming, 88  
 insomnia in, 98–9  
 benzodiazepines therapy, 217  
 non-benzodiazepine adjunctive therapy, 221, 222  
 nightmares, 87  
 sleep-related breathing disorders, 117, 120  
 anxiety disorders  
 ADHD and, 343
- management, 286  
 pediatric, 364, 366  
 and future sleep disorders, 360  
 polysomnography, 364  
 sleep disturbance, 363, 365  
 restless legs syndrome and, 139  
 sleep disturbance, 43, 248, 286, 293  
 treatment, 293, 365  
 specific disorders, 287  
*see also* generalized anxiety disorder (GAD)
- aphasia, Broca's area, 50  
 apnea *see* central sleep apnea; obstructive sleep apnea (OSA)
- apnea-hypopnea index (AHI)  
 ADHD, 347, 348  
 alcohol dependency, 316
- arousal disorders  
 confusional, 161–2, 163  
 idiopathic hypersomnia, 152  
 parasomnias, 102, 160–1  
 sleep-related enuresis, 171
- arousal state, in insomnia, 209–10  
 arousal, electrophysiologic measures, 209  
 arousal-related nuclei, 20–1  
 ASDs *see* autism spectrum disorders (ASDs)
- Aserinsky, Eugene, 2, 8  
 ASPD *see* advanced sleep phase disorder (ASPD)
- Asperger syndrome (AS), 377  
 atomoxetine, 319, 343, 346, 352
- attention deficits  
 excessive sleepiness, 101  
 obstructive sleep apnea, 112, 113, 114–15  
 sleep deprivation, 51–2, 148
- attention-deficit/hyperactivity disorder (ADHD), 343  
 adenotonsillectomy, 347, 351  
 future study needs, 352  
 in adulthood, 343  
 obstructive sleep apnea and, 120  
 psychiatric co-morbidities, 343, 344  
 sleep disturbance, 343, 344, 350  
 circadian rhythm sleep disorders, 194–5  
 diagnostic criteria, 343, 363  
 incidence of, 343  
 management, 350  
 medication-induced, 319, 320, 351, 352  
 primary, 346  
 restless legs syndrome, 133–4  
 treatment, 343, 345
- attitudes and beliefs, insomnia and, 98–9  
 auditory arousal thresholds, 177
- auditory perceptions, in dreams, 82  
 autism spectrum disorders (ASDs), 375, 376, 377  
 autoimmune disorders  
 fatigue defined, 99–100  
 in narcolepsy, 149  
 autonomic nervous system (ANS), 38, 152, 162  
 awake *see* wakefulness
- bacterial infection, 62  
 basal forebrain (BF), 15–16, 20  
 BD *see* bipolar depression (BD)
- bed partner  
 collateral information, 103  
 injury risk, 160–1, 335, 338  
 sleep disruption, 99, 171
- bed, excessive time in, 237  
 bedrest, for manic patients, 270  
 bedtime resistance  
 ADHD, 344, 349  
 autism spectrum disorders, 376
- behavior disorders, 165–77  
 behavioral assessments, 100–2, 179  
 behavioral circadian rhythm sleep disorders, 186–7  
 behavioral conditioning, 171  
 behavioral dysfunction  
 ADHD, 195  
 autism spectrum disorder, 376  
 developmental disorders, 373  
 fetal alcohol spectrum disorder, 380  
 Kleine-Levin syndrome, 153  
 mucopolysaccharidoses, 378  
 psychotic disorders, 307
- behavioral models, of insomnia, 210  
 behavioral therapies  
 ADHD, 343  
 anxiety disorders, 292  
 autism spectrum disorder, 376  
 manic patients, 270  
 substance-related insomnia, 323
- behavioral withdrawal, in sleep, 63  
 behaviorally-induced sleep loss, 99, 148–9, 191
- benzodiazepine antagonist, 154  
 benzodiazepine receptor agonists (BzRAs), 46  
 abuse and dependence, 318  
 anxiety disorders, 292  
 bipolar insomnia, 276–7  
 cognitive behavioral therapy compared, 234–5  
 depression-related

## Index

- benzodiazepine receptor agonists (BzRAs) (cont.)  
 obstructive sleep apnea and, 120  
 sleep-related eating disorder with, 173
- benzodiazepines, 46, 216–17  
 adjunctive therapy, 226–7, 258, 308  
 cognitive behavioral therapy compared, 234–5  
 for REM behavior disorder, 338  
 for sleepwalking/sleep terrors, 164  
 for substance-related insomnia, 322, *see also* clonazepam; estazolam; flurazepam; lorazepam; lormetazepam; nitrazepam; quazepam; temazepam  
 in depression, 226–7, 258  
 in psychotic disorders, 269–70, 276, 308  
 obstructive sleep apnea and, 121  
 risks with clozapine, 308  
 side-effects, 217
- beta waves, EEG activity, 14–15, 249–50
- BF (basal forebrain), 15–16, 20
- bidirectional model, sleep-psychiatry interface, 387–8
- binding problem, REM sleep, 8–9
- biomarkers, 191, 390
- bipolar depression (BD), 193, 270–1
- bipolar disorder, 266  
 circadian clock genes in, 273–4  
 delayed sleep phase disorder, 195  
 euthymia, 272–3  
 mania in, 266–70  
 sleep disturbance, 43, 228, 277–8, *see also* pediatric bipolar disorder (BPD)  
 bidirectional model, 388  
 evaluation, 274–5  
 management, 275–7
- bizarre elements, in dreams, 82
- blood glucose metabolism, 61, 62
- blood-oxygen-level-dependent (BOLD) fMRI, 51–2
- BMAL1 gene polymorphisms, 27–8, 193
- body temperature circadian rhythm, 188, 191
- body, and sleep, 68–9
- body-mind interaction, dreaming, 86
- BOLD (blood-oxygen-level-dependent) fMRI, 51–2
- borderline personality disorder, 195
- brain activation  
 and dream content, 86  
 in depression, 251–2, 362  
 in insomnia, 209  
 in obstructive sleep apnea, 114  
 in sleepwalking, 162
- brain development, REM sleep and, 8
- brain energy substrates, 64–5
- brain maps, changes in rCBF, 49
- brain plasticity  
 and memory processing, 65–6  
 and sleep, 69  
*in vitro/in vivo* studies, 66
- brain regions  
 cognitive impairments, 113–14  
 neurodegeneration in aging, 330, 331  
 sleep-inducing, 15
- brain rhythms, EEG monitoring in  
 sleep, 39–40
- brain tumor, 186–7
- brainstem, 15, 16–17
- breathing disorders  
 in panic disorder, 289, 337, *see also* sleep-related breathing disorders (SRBDs)  
 inspiratory stridor, 338
- breathing failure, post-stroke, 335
- breathing-related dream topics, 85–6
- bright light therapy, 192, 259  
 Alzheimer's disease, 333  
 circadian rhythm disorders, 192  
 for sleep-onset insomnia, 351  
 with sleep deprivation therapy, 271
- Broca's area aphasia, 50
- bromocriptine, 173
- bruxism, sleep-related, 141
- BTBD9 gene, 390
- bupropion, 140  
 for restless legs syndrome, 140  
 for stimulant drug side-effects, 352  
 in depression, 258  
 side-effects, 164
- cabergoline, 137
- caffeine  
 dependence, 319, 321
- calcium-mediated depolarization, 19
- cancer, hypersomnia, 155
- cannabis use, 316
- carbamazepine, 44  
 for restless legs syndrome, 138, 275  
 for sleepwalking/sleep terrors, 164  
 for substance-related insomnia, 322  
 sleep-related epilepsy, 175
- carbidopa, 173, 337  
 side-effects, 338
- cardiac arrhythmias, differentiation, 289
- cardiovascular diseases, insomnia and, 223
- cardiovascular system, in sleep, 38–9
- caregivers, 334, 338
- cataplexy  
 histaminergic neurons in, 18  
 orexin in cerebrospinal fluid, 18  
 treatment, 151  
 with narcolepsy, 149, 150
- catathrenia, 161, 171
- catechol-O-methyltransferase (COMT), 272
- CBT *see* cognitive behavior therapy (CBT)
- CBT-I *see* cognitive behavior therapy for insomnia (CBT-I)
- cellular changes, synaptic plasticity, 68
- cellular circadian rhythmicity, 27–8
- central hypersomnia syndromes, 149–51
- central nervous system disorders, 43, 167
- central sleep apnea, 111, 317, 337, 378
- cerebellum, damage, 114
- cerebral blood flow (CBF)  
 in sleepwalking, 162  
 NREM sleep, 47  
 REM sleep, 48–50
- cerebral cortex, deafferentation, 15
- cerebrospinal fluid (CSF), in  
 narcolepsy, 149
- c-Fos protein expression, 16
- chest examination, 104
- childhood, 372, 374, 375  
 abuse in, 164, 291, 364  
 anxiety, 365  
 anxiety disorders, 286, 358, 363, 366  
 generalized anxiety disorder, 290  
 post-traumatic stress disorder, 291, 364  
 separation anxiety disorder, 290  
 specific phobias, 287, 290  
 treatment, 292
- arousal disorders, 163
- delayed sleep phase disorder, 194–5
- depression, 358–63
- insomnia, 359

## Index

- sleep-related enuresis, 171  
 sleep-related rhythmic movement disorder, 140  
 sleep-wake changes, 42  
 sleepwalking in, 162, 164,  
   *see also* attention-deficit/  
   hyperactivity disorder  
   (ADHD); developmental  
   disorders; pediatric bipolar  
   disorder (BPD)  
 cholinergic system  
   brain development, 8  
   depression and, 257  
   in arousal mechanism, 15–16  
   in schizophrenia, 305  
   pontine, 3–4, 23, 48  
   reciprocal interaction model, 24–5  
 cholinesterase inhibitors, 335  
 chromosome linkages, familial restless  
   legs syndrome, 134  
 chronic medical conditions,  
   hypersomnia, 154–5  
 chronic pain, 46, 228, 236  
 chronic renal failure *see* renal disease  
 cingulate gyrus, in total sleep  
   deprivation, 252  
 circadian clock genes *see* CLOCK gene  
   polymorphisms  
 circadian rhythm, 26–9  
   hormone release, 39  
   in restless legs syndrome, 139  
   in sleep deprivation, 62  
   sleep regulation, 13, 26  
   transcription factors in, 27–8,  
     *see also* diurnal rhythm  
     of somnogens  
 circadian rhythm disturbance, 99  
   adolescent depression, 362  
   alcohol abuse and, 314  
   autism spectrum disorders, 376  
   by daytime behaviors, 97  
   endophenotypes, 390  
   in Alzheimer's disease, 331–4  
   in euthymic bipolar subjects, 272–3  
   in older patients, 330  
   in schizophrenia, 306  
   MDMA use, 321  
   sleep-wake changes, 99  
 circadian rhythm manipulation,  
   for manic patients, 270  
 circadian rhythm sleep disorders  
   (CRSDs), 186–7  
   ADHD and, 348  
   behavioral, 186–7  
   depression and, 251  
   diagnosis, 189–91, 393  
   in psychiatry, 192–7  
   insomnia in, 205  
   monitoring, 190–1  
   pathophysiology, 187–9  
   treatment, 192  
     melatonin therapy, 222  
     phase advance therapy, 257, 259  
 citalopram, 140, 292, 352  
 clinical interview *see* history-taking  
 clitoral engorgement, during sleep, 39  
 CLOCK gene polymorphisms  
   ADHD adults, 194  
   bipolar disorder, 273–4  
   circadian rhythm, 27–8, 272  
   circadian rhythm sleep disorders,  
     27–8, 193  
 clomipramine, 196–7  
 clonazepam  
   adjunctive therapy, 226–7, 276  
   for insomnia, 217  
   mania, 269–70  
   REM sleep behavior disorder,  
     169, 338  
   sleep-related eating disorder, 173  
   sleepwalking/sleep terrors, 164  
 clonidine, 169, 177, 352, 377  
 clozapine, 196, 308  
 CNS sedating substances, 314  
 CNS stimulants, 319  
 cocaine  
   abuse and dependence, 319, 322, 323  
 codeine, 173  
 cognitive behavior therapy (CBT),  
   170, 291, 359, 365  
 cognitive behavior therapy for  
   insomnia (CBT-I), 233, 238–43  
   benzodiazepines compared, 234–5  
   chronic pain, 236  
   client non-compliance, 242–3  
   depression-related insomnia, 259  
   for bipolar insomnia, 276  
   pharmacotherapy with, 235, 241–2  
   psychiatric outcomes, 236, 388  
   substance-related insomnia, 323  
 cognitive behavioral models, of  
   insomnia, 210–11  
 cognitive function  
   chronic insomnia, 97, 233  
   in Alzheimer's disease, 334  
   in dementia with insomnia, 340  
   melatonin therapy, 334  
   obstructive sleep apnea, 112–13,  
     113–15, 114–15, 334  
   psychotic disorders, 306, 307  
   restless legs syndrome diagnosis,  
     131, 132  
   sleep deprivation, 50–2, 148  
 cognitive models, of insomnia, 210  
 cognitive theories, sleep function,  
   65–8, 69  
 cognitive-experiential model, dream  
   interpretation, 87  
 color perception, in dreams, 82  
 co-morbidity  
   history-taking, 103  
   in insomnia, 96, 236–7  
 complex nocturnal visual  
   hallucinations, 172  
 conduct disorder (CD), 343  
 confusional arousals, 161–2, 163  
 congestive heart failure (CHF), 154–5  
 consciousness, development of, 8  
 consultations, sleep medicine, 107  
 continuity hypothesis, 84–5  
 continuous positive airway pressure  
   (CPAP), 112, 115  
   anxiety and, 120  
   co-morbid psychotic disorders, 306  
   dementia patients and, 334  
   for sleepwalking, 165  
   modafinil adjuvant therapy, 122  
   mood changes, 117, 119–20  
   sexsomnia, 174  
 coping strategies, maladaptive in  
   insomnia, 237–8  
 cortical regions  
   activation, 19–20, 50, 114  
   cerebral blood flow, 47  
   neurocognitive system, 50–1, 51–2,  
     210–11  
   neuroplasticity, 66–7,  
     *see also* occipital cortex  
 corticobasal deg

## Index

- daytime sleepiness, 40–1, 101–2  
 ADHD, 345, 348, 349, 350, 353  
 decreased in insomniacs, 97  
 dopamine agonist-induced, 338
- deep sleep *see* slow-wave sleep (SWS)
- delayed sleep phase disorder (DSPD), 187  
 ADHD, 194–5  
 circadian rhythm sleep disorders, 186, 187–9, 191  
 depression and, 193  
 obsessive-compulsive disorder, 195–6  
 personality disorders and, 195  
 SSRI-induced, 196
- delta frequency, NREM sleep, 18–19
- Dement, William, 2, 5
- dementia, 331  
 and REM sleep disorders, 167  
 circadian rhythm sleep disturbance, 186–7  
 frontal-subcortical, 339  
 frontotemporal, 339  
 Huntington's disease, 339  
 prion diseases, 340  
 sleep disturbance, 330, 331, 340  
*see also* Alzheimer's disease; Parkinson's disease dementia (PDD); vascular dementia
- dementia with Lewy bodies (DLB), 167, 172, 340
- dental damage, sleep-related eating disorders, 173
- depolarizations, in neocortical slow oscillations, 20
- depression  
 and obstructive sleep apnea, 115–20  
 cardiovascular mortality and, 38–9  
 circadian rhythm sleep disorders, 193–4, 251  
 in restless legs syndrome, 138–40  
 in sleep-related breathing disorders, 116  
 insomnia and, 234, 387  
 insomnia treatment, 236, 257–9, 259–60, 392  
 long-term, 66, 68  
 negatively-toned dreams, 85  
 nicotine effects, 320  
 risk factors, 253–4, 255, 256, 359–60  
 serotonin levels, 16–17  
 sleep deprivation in, 252–3  
 sleep disturbance and, 155, 253–7  
 in children, 358–63, 359–60  
 treatment response, 256,  
*see also* antidepressants; bipolar depression (BD)
- depressive disorders, 247  
 insomnia co-morbidity, 96, 208, 211  
 sleep disorders in, 43, *see also* major depressive disorder (MDD)
- Descartes, Rene, 1
- detoxification theories, in sleep, 63–4
- developmental disorders, 371, 372, 382
- developmental plasticity, 66–7, 68
- diabetes  
 risk in sleep quantity, 39, 61  
 secondary restless legs syndrome, 135
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV)  
 nosologic standard, 392  
 on ADHD, 343  
 on dementia, 331  
 on insomnia, 204  
 on major depressive disorder, 247  
 on psychotic disorders, 298, 300  
 on substance-induced sleep disorders, 314
- differential diagnosis, in sleep disorders, 104
- Digit Vigilance–Time test, 115
- digital period analysis (DPA), 249–50
- dim light melatonin onset (DLMO), 348
- diphenhydramine, 225–6, 308, 352  
 abuse and dependence, 318
- diphenylhydantoin, 175
- disorders of arousal *see* arousal disorders
- dissociative disorders  
 polysomnography, 175  
 sleep-related, 161, 170, 171
- dissociative identity disorders, 170
- diurnal dissociative disorders, 170
- diurnal rhythm, of somnogens, 25
- divorced/separated/widowed status, 206
- DLB (dementia with Lewy bodies), 167, 172, 335
- donepezil, 169, 333
- dopamine (DA), 17
- dopamine agonists  
 antipsychotics and, 308  
 bipolar disorder, 275  
 dementia with Lewy bodies, 335  
 panic disorder, 336, 337, 338  
 restless legs syndrome, 134, 137–8  
 side-effects, 134, 137–8, 338  
 sleep-related movement disorders, 130, *see also* methylphenidate; modafinil; pramipexole; ropinirole; rotigotine
- dopamine reuptake inhibitor  
*see* bupropion
- dopaminergic antagonists, 132
- dopaminergic drugs  
 for restless legs syndrome, 136  
 for sleep-related eating disorder, 173
- dopaminergic system, 134  
 neurons, 17
- dorsal arousal pathway, activation, 15
- dorsomedial nucleus (DMH), 28–9
- Down syndrome (DS), 378
- doxepin  
 dissociative disorder, 171  
 insomnia, 223  
 sleep terrors, 164, 165  
 sleepwalking, 164, 165
- doxylamine, 225–6
- dream collection, 81
- dream consciousness, 6–8
- dream content, 83–4, 86  
 eye movements, 86  
 in narcolepsy, 86  
 location bias, 81
- dream content analysis, 81–2  
 in psychoanalysis, 1  
 in psychotherapy, 87  
 phenomenology, 82–3
- dream deprivation, 2
- dream diaries, 81, 82
- dream emotions, 82
- dream rehearsal/enactment, in nightmares, 166, 177
- dream state, REM sleep, 79
- dream studies, 80–1
- dreaming, 88  
 cortical activation, 49–50  
 in adulthood, 9  
 in history, 160  
 in REM sleep, 7, 9–10  
 protoconscious state, 6  
 psychosis-like quality, 4  
 waking life and, 9, 84
- dreams, 79–80, 89  
 aggressive, 81  
 and psychopathology, 84–5  
 creative inspiration from, 87  
 effect on waking life, 86–7  
 functions of, 87–9  
 lucid dreams, 80, 86  
 negatively-toned, 82, 85  
 recall, 81, 85

## Index

- drug-induced sleep disorders, 44–7  
 parasomnias, 169  
 REM sleep behavior disorder, 168  
 restless legs syndrome, 135–6  
 DS (Down syndrome), 378  
 DSPD *see* delayed sleep phase disorder (DSPD)  
 duloxetine, 140, 258  
 dysfunctional beliefs, in insomnia, 98–9, 210
- early morning awakening, 376  
 early-onset restless legs syndrome, 132, 134  
 eating disorder *see* sleep-related eating disorder (SRED)  
 ECG (electrocardiography), 40, 162  
 ecstasy (club drug) *see* methylenedioxymethamphetamine (MDMA)  
 EDS *see* excessive daytime sleepiness (EDS)  
 education  
   for good sleep habits, 148–9  
   in psychiatry, 393  
   non-compliant patients, 243  
 EEG *see* electroencephalography (EEG)  
 elderly people  
   insomnia risk factor, 206  
   psychosis, 138  
   sleep–wake changes, 43, 248  
 electrocardiography (ECG), 40, 162  
 electrode placement  
   EEG sleep monitoring, 39–40  
   EOG sleep monitoring, 40  
 electroencephalography (EEG), 37, 39–40  
   chronic medical conditions, 154  
   depression, 361  
   insomnia, 210–11  
   major depressive disorders, 43, 249–50  
   NREM sleep, 18–19, 47–8, 210–11  
   obstructive sleep apnea, 175  
   REM sleep, 2, 21  
   schizophrenia, 304  
   sleep stages, 36–8  
   sleepwalking/sleep terrors, 162, 163  
   vigilance states, 14–15, 19,  
     *see also* high-density  
     electroencephalography  
     (hd-EEG)  
 electromyography (EMG), 39–40  
   polysomnography, 40  
   restless legs syndrome, 134  
   sleep stages, 36–8  
   sleepwalking/sleep terrors, 162  
   vigilance states, 14–15  
 electrooculography (EOG), 2, 36–8, 39–40
- EMG *see* electromyography (EMG)  
 emotions  
   cataplexy-induction, 150  
   in dreams, 82  
   noradrenaline in, 17  
   sleep deprivation and, 52  
 employment  
   history-taking, 104  
   impact of sleep problems, 138, 148, 233  
 encephalitis lethargica, 15, 154  
 endocrine biology, 61–2  
   disorders, 155  
   ontogeny, 68–9  
 endophenotypes, 273–4, 396  
 endoplasmic reticulum (ER), 64  
 endozepine-4, 154  
 energy homeostasis, leptin in, 39, 62, 119  
 energy substrates, 64–5  
 enuresis, sleep-related, 161, 171  
 EOG (electrooculography), 2, 36–8, 39–40
- epilepsy  
   childhood, 373  
   Down syndrome, 378  
   sleep-related, 175,  
     *see also* antiepileptic drugs  
     (AEDs)  
 epileptiform activity, obstructive sleep apnea, 175  
 Epworth Sleepiness Scale (ESS), 102  
   daytime sleepiness, 41  
   excessive daytime sleepiness, 118, 147, 149  
   excessive sleepiness, 101  
   insomnia assessment, 205–6  
 ergot-dopamine agonists, 137  
   insomnia assessment,  
     *see also* pergolide  
 ES *see* excessive sleepiness (ES)  
 escitalopram, 140, 292  
 estazolam, 217  
 eszopiclone  
   abuse and dependence, 318  
   bipolar insomnia, 276–7  
   chronic pain, 228  
   for insomnia, 217–22, 258  
   mood disorders, 227, 258, 292
- ethnicity  
   insomnia risk, 206  
   restless legs syndrome, 132  
 euthymia, sleep in, 272–3  
 evening agitation, 331, 332  
 evening limb pain, 130–1  
 evening sleepiness, excessive, 100  
 evolutionary theories, on sleep, 59–60, 68, 69  
 excessive daytime sleepiness (EDS), 156
- alerting agents for, 152  
 behaviorally-induced sleep loss, 148–9  
 diagnosis, 146, 149–50, 191  
 epidemiology, 146  
 history-taking, 99–102  
 hypersomnias, 146, 152–3  
 narcolepsy, 149–50  
 obstructive sleep apnea, 112, 122  
 patient counseling, 156  
 patient evaluation, 147–8  
 polysomnography, 107,  
   *see also* daytime sleepiness;  
   traffic accidents  
 excessive sleepiness (ES)  
   differential diagnosis, 104  
   history-taking, 99–102  
   serum laboratory tests, 106–7  
   temporal pattern, 100  
 excitation, NA activity in, 17  
 executive functioning, deficits, 113, 114–15, 343  
 exploding head syndrome, 161  
 eye disorders, phototherapy  
   and, 241  
 eye movement desensitization and  
   reprocessing therapy  
   (EMDR), 177  
 eye movement disorder, 338  
 eye movements, 40, 86
- factitious parasomnia, 177  
 failure to thrive, pediatric insomnia, 372  
 family history  
   ADHD, 346  
   circadian rhythm sleep disorder, 189, 193  
   history-taking, 103  
   idiopathic hypersomnia, 152  
   insomnia risk, 2

## Index

- fears, 80–1, 289, 363  
 feeding, and satiety, 62  
 ferritin levels, reduced, 132, 133, 134  
 fetal alcohol spectrum disorder (FASD), 380  
 fetal life, sleep–wake changes, 42  
 fibromyalgia, 154, 226  
 final common pathway model, 268  
 financial costs, of insomnia, 211  
 fine motor coordination, 114  
 flip-flop switch model, 13, 20–1  
 flumazenil, 154  
 fluoxetine, 121  
   adjunctive therapy in insomnia, 217, 221  
   anticataleptic agent, 151  
   mood disorders, 363  
   pediatric insomnia, 366  
   side-effect, 140  
   sleep–wake cycle and, 196–7  
 flupentixol, 196, 197  
 flurazepam, 121, 217  
 fluvoxamine, 196, 197  
 fMRI *see* functional magnetic resonance imaging (fMRI)  
 food availability, in circadian rhythmicity, 28–9  
 fragile X syndrome, 380  
 fragmented sleep *see* sleep fragmentation  
 Freud, Sigmund, 1–2, 160  
 frontal lobe  
   dysfunction, 113–14,  
     *see also* prefrontal model,  
     in obstructive sleep apnea  
 frontal lobe seizures, 175  
 frontotemporal dementia, 339  
 functional magnetic resonance imaging (fMRI)  
   BOLD (blood-oxygen-level-dependent), 51–2  
   functional neuroanatomy, 47–8  
   in new research, 391  
   inhibitory efficiency studies, 52  
   learning and neural plasticity, 50  
   sleep deprivation effects, 51–2  
 functional neuroanatomy  
   neuroimaging techniques, 47–52  
   of arousal, 209–10  
 functions of sleep *see* sleep functions  
 funding, research studies, 388  
 future sleep–psychiatry interface, 387  
 GABA  
   GABA-A receptors, 216–21  
   GABAergic drugs, 177  
   GABAergic inhibition, 19  
   GABAergic neurons, 24–5  
   GABAergic preoptic nuclei, 20  
   gabapentin, 138, 226, 277, 322  
   GAD *see* generalized anxiety disorder (GAD)  
   galantamine, 333  
   gamma waves, on EEG, 14–15  
   gamma-aminobutyric acid (GABA) *see* GABA  
   gastrointestinal diseases, insomnia and, 236  
 gender  
   circadian rhythm alterations, 362  
   depression, 361, 362  
   dream content, 83  
   insomnia risk factor, 206  
   restless legs syndrome, 132  
 generalized anxiety disorder (GAD), 288  
   ADHD co-morbidity, 345  
   diagnosis, 286  
   in childhood, 364  
   insomnia in, 227, 288  
   pharmacotherapy, 388  
   sleep disturbance, 286, 290  
 genetic expression  
   BTBD9 gene, 390  
   endoplasmic reticulum protein biogenesis, 64  
   polymorphisms  
     bipolar depression, 272  
     mood and circadian rhythm disorders, 193  
 genetic inheritance  
   fatal familial insomnia, 340  
   Huntington's disease, 339  
 genetic mutations, Alzheimer's disease, 332  
 genetic susceptibility  
   childhood depression, 359  
   circadian rhythmicity, 27–8, 189  
   restless legs syndrome, 134  
 genetic upregulation, in sleep, 68  
 genetics, new research, 389  
 geniculate nucleus *see* lateral geniculate nucleus  
 ghrelin, 39, 62  
 glial glycogen, 65  
 glucose metabolism (CMRGlu), 51  
 glutamate release, 63  
 glutathione, 63  
 glycogen synthase kinase (GSK3- $\beta$ )  
   gene polymorphisms, 272, 273–4  
 glycogen, cortical, 65  
 goal-setting, and patient compliance, 243  
 gray matter volume, diminished, 114  
 groaning, sleep-related, 161, 171  
 group therapy, for restless legs syndrome patients, 140  
 growth hormone (GH)  
   deficiency, 155  
   release during sleep, 39, 61  
   sleep deprivation and, 39  
 growth hormone-releasing hormone (GHRH), 252  
 GSK3- $\beta$  gene polymorphisms, 272, 273–4  
 habits *see* sleep habits/hygiene  
 hallucinations  
   dementia with Lewy bodies, 335  
   differential diagnosis, 307  
   excess sleepiness and, 150  
   panic disorder, 337  
   schizophrenia, 84, 300  
   sleep-related, 161, 172  
 haloperidol, 46, 196, 197  
 Hamilton depression scale, 118  
 hd-EEG (high-density electroencephalography), 47, 390  
 head noises, 172  
 head trauma  
   hypersomnia, 154  
   secondary circadian rhythm disorder, 186–7  
 health risks, sleep-related eating disorder, 173  
 healthcare costs, of insomnia, 211, 234  
 hearing impairment, insomnia, 373  
 heart disease *see* cardiovascular diseases, insomnia and  
 Hebbian synaptic plasticity, 67  
 heroin, effects on sleep, 46  
 high-density electroencephalography (hd-EEG), 47, 390  
 hippocampal–neocortical interactions, 67  
 hippocampus  
   potential induction, 66  
   REM sleep, 23  
 histamine, 17–18  
 histamine receptor antagonists, 308  
 REM sleep, *see also* antihistamines  
 histaminergic neurons, 17–18  
 history-taking, 107  
   bipolar disorder, 274  
   circadian rhythm sleep disorders, 189  
   dementia with insomnia, 340  
   excessive sleepiness,

## Index

- pediatric insomnia, 373  
 sleep disorder scales and inventories, 106  
 sleep patterns, 99  
 sleep-related complaints, 95–6  
 tests in, 106–7  
 homeostatic regulation, 13, 60–1  
   in two-process model, 26  
   process S, 25–6  
 HPA *see* hypothalamic-pituitary-adrenal (HPA) axis  
 human leukocyte antigen (HLA), 149  
 human period3 gene (*hper3*)  
   *see* period 3 genes  
 hunger-promoting hormones, 39  
 Huntington's disease (HD), 339  
 hyperactivity, in ADHD, 343  
 hyperarousal  
   caffeine and, 321  
   childhood anxiety disorders, 363  
   insomnia pathophysiology, 209–10  
 hypercarbia, 113–14  
 hyperkinetic disorders, 343, 393  
 hyperpolarizations, neocortical, 20  
 hypersomnia  
   bipolar disorder, 270–1, 275  
   childhood depression, 359  
   excessive sleepiness, 100  
   idiopathic, 101, 151–3, 191  
   major depressive disorders, 247  
 hypersomnias of central origin, 146, 149–51  
   chronic medical conditions, 154–5  
   idiopathic, 151–3, 153–4  
   menstrual-related, 153  
   nervous system disorders, 154  
   psychiatric disorders, 155–6  
   recurrent, 153–4  
 hypervigilance, childhood anxiety disorders, 363  
 hypnagogic hallucinations, 37, 150, 172  
 hypnogram, 42  
 hypnopompic hallucinations, 150, 172  
 hypnosis, 164–5, 171, 177  
   recurrent, *see also* self-hypnosis  
 hypnotic drugs  
   anxiety disorders, 292  
   cognitive behavioral therapy and, 241–2  
   effects on sleep, 46  
   risks in Alzheimer's disease, 333,  
     *see also* benzodiazepine  
     receptor agonists (BzRAs);  
     eszopiclone  
 hypocretin *see* orexin  
 hypothalamic-pituitary-adrenal (HPA) axis  
   anxiety disorders, 365  
   depression, 252  
   hormones, 39  
   hyperarousal in insomnia, 209  
   NREM sleep, 61  
 hypothalamus  
   dorsomedial nucleus, 28–9  
   orexin system dysfunction, 149  
   suprachiasmatic nucleus, 187–8,  
     *see also* anterior  
     hypothalamus, damage; lateral  
     hypothalamus; posterior  
     hypothalamus  
 hypothyroidism, 155, 378  
 hypoxemia, 113–14, 118  
 ICSD *see* International Classification of Sleep Disorders (ICSDs)  
 identity disorder, dissociative, 170  
 idiopathic hypersomnia, 101, 151–3, 191  
 idiopathic insomnia, 248  
 idiopathic recurring stupor, 153–4  
 idiopathic restless legs syndrome, 132, 134  
 imagery rehearsal therapy (IRT), 87, 170, 292  
 imipramine, 164, 171  
 immaturity, REM sleep and, 8  
 immune system, and sleep, 62–3, 68–9  
 impulse control lacking  
   bipolar disorder, 275  
   in ADHD, 343  
   insufficient sleep, 148  
 inappropriate responses, sleep deprivation and, 52  
 inattention, in ADHD, 343  
 infancy, sleep–wake changes, 42  
 infectious agents, EDS and hypersomnia, 154  
 infertility, risk in melatonin use, 222  
 inflammatory mediators, 118–19, 154  
 information processing speed, 115  
 inhibitory activity, 17, 52  
 inhibitory neurotransmitter, 20  
 initial insomnia, in anxiety disorders, 248  
 initiating sleep, prevention and treatment, 374  
 injury risk  
   dream-enactment behavior, 166  
   parasomnias, 160–1  
   REM sleep behavior disorder, 167  
   sleepwalking/sleep terrors, 163, 164  
 input–output gates, AIM model, 5, 6  
 insomnia, 203, 211–12  
   assessment, 203–4, 205–6  
   behavioral model, 237–8  
   chronic, 96  
   chronic hyperarousal, 321  
   classification, 204, 236–7  
   diagnosis, 203–4  
   differential diagnosis, 104, 204–5  
   dreams and, 85  
   epidemiology, 206, 234  
   evaluation, 205–6  
   history-taking, 96–9  
   impact of, 211, 233–6  
   in older patients, 330  
   medical diseases with, 208  
   natural history, 208, 233  
   pathophysiology, 17, 209–10  
   risk factors, 206–8, 234  
   serotonin depletion, 16  
   serum laboratory tests, 106–7  
   severity, 248  
   sleep patterns, 99  
   smoking status and, 320  
   trait characteristics, 237  
   treatment, 234–5, 257–9,  
     *see also* sleep-onset insomnia (SOI), in ADHD  
     justification, 235–6  
     pharmacotherapy, 216–26, 228–9  
 insomnia disorders  
   differential diagnosis, 191  
   new criteria in DSM, 393  
 insomnia severity index (ISI), 97–8  
 insulin sensitivity, sleep loss and, 39  
 interleukin 1B (IL-1B), NREM sleep, 62  
 International Classification of Diseases (ICD), 392  
   on ADHD, 343  
   on insomnia, 204  
 International Classification of Sleep Disorders (ICSDs)  
   excessive daytime sleepiness, 146  
   insomnia, 204  
   major depressive disorder, 247–8  
   substance-induced sleep disorders, 314  
 interpersonal

## Index

- lamotrigine, 275  
 language problems, ADHD  
     co-morbidity, 343  
 late-onset restless legs syndrome, 132  
 lateral geniculate nucleus, 21–3  
 lateral hypothalamus, 18  
 laterodorsal tegmental neurons  
     in REM sleep, 23  
     in wakefulness, 15, 16  
     reciprocal interaction model, 24–5  
 laterodorsal tegmental nuclei, 15  
 laughter, cataplexy-induction, 150  
 L-DOPA *see* levodopa (L-DOPA)  
 learning deficits, sleep deprivation,  
     68, 148  
 learning disability  
     ADHD co-morbidity, 343  
     pediatric insomnia, 373  
     syndromes, 377  
 learning, neuroplasticity, 50  
 leg cramps, nocturnal, 141  
 leg pain, nocturnal, 131–2, 141  
     syndromes, *see also* restless legs  
     syndrome (RLS)  
 leptin, 39, 62, 119  
 levodopa (L-DOPA)  
     for panic disorder, 337, 338  
     for restless legs syndrome, 137  
     for sleep-related eating disorder, 173  
     side-effects, 169, 338  
 Lewy bodies  
     in panic disorder, 336,  
     *see also* dementia with Lewy  
     bodies (DLB)  
 life-cycle, sleep–wake changes, 42–3  
 light cues, in circadian timing, 188  
 light sensitivity alterations, in bipolar  
     patients, 273  
 light therapy *see* bright light therapy  
 limb movements  
     dream content, 86  
     polysomnography, 40  
     post-traumatic stress disorder, 176  
     REM sleep behavior disorder, 169  
 limbic-subcortical responses, 52  
 limit-setting disorder, ADHD  
     co-morbidity, 344  
 lithium  
     side-effects, 135, 164, 275  
     with sleep deprivation therapy, 271  
 locus coeruleus (LC), 17, 23–4  
 long-term potentiation (LTP), 66, 68  
 lorazepam  
     for insomnia, 217, 322  
     in mania, 269–70  
     in panic disorder, 338  
     risks with clozapine, 308  
 lormetazepam, 226–7  
 low threshold spike (LTS), 19  
 LTP (long-term potentiation), 66, 68  
 L-tryptophan, 121  
 magnetic resonance imaging  
     (MRI), 47  
     *see* dreams, *see also* functional  
     magnetic resonance imaging  
     (fMRI)  
 magnetic resonance spectroscopy  
     (MRS), 47, 391  
 magnetoencephalogram (MEG),  
     19–20  
 maintenance of sleep, 374  
 maintenance of wakefulness test  
     (MWT), 41, 107, 148  
 major depressive disorder (MDD)  
     ADHD co-morbidity, 345  
     circadian rhythm sleep disorder  
     and, 193  
     differential diagnosis, 153  
     in childhood, 358, 366  
     insomnia and, 211, 250–1, 388  
     therapies, 217, 221, 222, 226–7  
     insomnia as risk factor, 234  
     obstructive sleep apnea and, 115–16  
     relapse/recurrence, 253–5, 256  
     restless legs syndrome and, 139, 140  
     sleep abnormalities in, 43,  
     247–51, 255  
     sleep deprivation therapy, 392  
     sleepiness in, 155  
 maladaptive coping strategies, in  
     insomnia, 237–8  
 malingering, factitious sleep  
     disorder, 177  
 Mallampati airway classification, 104,  
     106, 111–12  
 mania  
     in bipolar disorder, 266–7, 363  
     insomnia and, 228  
     sleep duration and, 267–9  
     sleep reduction in, 238, 269  
     treatment, 238, 269–70  
     triggers for, 241, 268  
 marital status, insomnia risk, 206  
 masochistic dreams, 85  
 mastery hypothesis, on dreaming, 88  
 MDD *see* major depressive disorder  
     (MDD)  
 MDMA (methylenedioxmeth-  
     amphetamine), 321  
 median preoptic nucleus (MnPN), 20  
 medical conditions  
     insomnia as risk factor, 234  
     insomnia co-morbidity, 205, 208,  
     236–7  
 medical history, 103  
 medical outcomes, insomnia  
     treatment, 235  
 medications  
     effects on sleep architecture, 44–7  
     history-taking, 103  
     hypersomnia induced by, 155–6  
     insomnia precipitated by, 96  
     pediatric insomnia, 373  
     restless legs syndrome exacerbation  
     by, 139–40  
 melancholic depression, 38  
 melanin-concentrating hormone  
     (MCH), 62  
 melanopsin, 28  
 melatonin (endogenous)  
     circadian rhythmicity, 28, 187–8  
     disorders, 191, 348  
     in Alzheimer's disease, 332  
     non-24-hour sleep–wake  
     syndrome, 191  
     release timing, 39  
 melatonin MT1/MT2 receptor  
     agonist, 392  
 melatonin receptor agonists, 222, 277  
     release timing, *see also* ramelteon  
 melatonin therapy  
     ADHD, 194, 351, 352  
     Alzheimer's disease, 333  
     autism spectrum disorder, 377  
     bipolar insomnia, 277  
     circadian rhythm sleep  
     disorder, 192  
     delayed sleep phase disorder, 194  
     developmental disorders, insomnia

## Index

- methadone maintenance treatment (MMT), 317  
 methamphetamine, 319, 323  
 methylidopa, 169  
 methylenedioxymethamphetamine (MDMA), 321  
 methylphenidate  
   abuse and dependence, 319  
   ADHD, 343  
   side-effects, 345, 351, 352  
 midbrain  
   dopaminergic neurons, 17  
   serotonin 5-HT, 16–17  
 midbrain tegmentum, 15  
 mind–body interaction, 1, 86  
 mirtazapine, 224  
   anxiety disorders, 292  
   for substance-related insomnia, 323  
   major depressive disorder, 227  
   obstructive sleep apnea, 121  
   side-effects, 135–6, 139, 224, 352  
 modafinil  
   adjunctive treatment, 242, 258  
   for excessive daytime sleepiness, 149  
   for hypersomnia, 153, 275  
   for narcolepsy, 151  
   for substance-related insomnia, 323  
   obstructive sleep apnea and, 122  
 mode of processing, AIM model, 5  
 modulatory ratio, AIM model, 5, 6  
 molecular changes, synaptic plasticity, 67, 68  
 monoamine oxidase inhibitors (MAOIs), 44  
   depression-induced insomnia, 258  
   nightmare disorder, 169  
   panic disorder, 338  
   REM sleep behavior disorder, 167  
 mood changes  
   insufficient sleep, 148  
   obstructive sleep apnea, 117, 119–20  
 mood disorders  
   ADHD co-morbidity, 343  
   children, 358, 365, 366  
   circadian rhythm sleep disorders, 193–4  
   in restless legs syndrome, 138–40  
   non-pharmacological treatment, 365  
 mood regulation hypothesis, on dreaming, 88  
 morning awakening difficulties  
   ADHD, 349  
   childhood depression, 358, 359  
   confusional arousal, 162  
   excessive sleepiness, 100  
 morphine, 46  
 mortality rates  
   restless legs syndrome and, 138  
   sleep quantity and, 61  
 mother–child bonding, sleep–wake patterns, 195  
 motivational approach, to therapy, 242  
 motor activation, 335  
   bipolar mania, 269  
   post-traumatic stress disorder, 176  
   REM sleep behavior disorder, 167  
 motor hyperactivity, in mania, 267  
 motor learning, reduced, 304  
 motor vehicle accidents *see* traffic accidents  
 mouth/nose airflow, 40  
 movement disorders  
   alcohol abuse and, 316,  
     *see also* Parkinson's disease (PD); periodic limb movement disorder (PLMD); restless legs syndrome (RLS)  
   in ADHD, 348, 349, 353  
 MRI *see* magnetic resonance imaging (MRI)  
 MRS *see* magnetic resonance spectroscopy (MRS)  
 MSLT *see* multiple sleep latency test (MSLT)  
 mucopolysaccharidoses (MPS), 378  
 multiple sclerosis, 99–100  
 multiple sleep latency test (MSLT), 41, 150  
   ADHD, 348, 350  
   bipolar depression, 271  
   daytime polysomnography, 107  
   excessive daytime sleepiness, 147–8  
   idiopathic hypersomnia, 153  
   major depressive disorder, 155  
   narcolepsy diagnosis, 150  
   sleepwalking/sleep terrors, 163  
   substance dependence, 319  
 multiple system atrophy (MSA), 335  
 Munchausen syndrome, 177  
 muscarinic receptors, 305  
 muscle activity, EMG monitoring, 40  
 muscle atonia, in REM sleep, 23–4, 336, 337  
 muscle tone, NREM sleep, 37  
 muscle twitches, positive myoclonus, 37  
 myocardial infarction, 61  
 N1 stage NREM sleep, 37  
 N2 stage NREM sleep, 37  
 N3 stage NREM sleep, 37–8  
 NA *see* noradrenaline (NA)  
 napping, 150  
   excessive sleepiness, 101  
   idiopathic hypersomnia, 152–3  
   narcolepsy, 149–50  
   older patients, 330, 331  
   panic disorder, 337  
 narcolepsy, 149  
   age of onset, 149  
   central hypersomnia syndrome, 149  
   diagnosis, 149, 191, 307  
   dream recall frequency, 86  
   excessive sleepiness in, 100, 149–50  
   in children, 372  
   napping in, 149–50  
   orexin system, 18, 21  
   polysomnography, 40  
   post-traumatic, 154  
   sleep latency values, 41  
   treatment, 150–1, *see also* cataplexy  
 nasal pressure recording, 163  
 nasal pressure transducers, 40  
 neck circumference, 104  
 nefazodone, 177  
 negatively-toned dreams, 82, 85  
 neocortical slow oscillations, 19–20  
 neocortical–hippocampal interactions, 67  
 neonatal development, 42, 60, 66–7  
 nervous system disorders, hypersomnias in, 154  
 neural systems, vigilance state regulation, 13–25  
 neural theories, sleep function, 63–5  
 neurobiology  
   depression and sleep disturbance, 118, 256, 257  
   sleep medicine studies, 2–4  
 neurochemical hypotheses, in total sleep deprivation, 252  
 neurocognitive impairment, excessive daytime sleepiness, 156  
 neurocognitive model, of insomnia, 210–11  
 neurodegeneration  
   disease taxonomy, 339  
   in aging, 330, 331  
   in Alzheimer's disease, 332  
   in hypersomnia, 154  
   REM sleep behavior disorder, 16

## Index

- neuroimmune interactions, mood changes, 119
- neuroleptics  
 for nightmares, 169, 177  
 side-effects, 132, *see also* flupentixol; haloperidol; quetiapine; risperidol  
 parasomnias, 164, 169  
 risk in dementia with Lewy bodies, 335  
 sleep-related movement disorders, 130, 139  
 sleep-wake cycle disruption, 196
- neurological disorders  
 hypersomnia, 154  
 secondary restless legs syndrome, 135
- neurological examination, 104
- neuromuscular disorders, polysomnography, 40
- neuronal damage, in sleep deprivation, 63–4
- neuronal excitability, after sleep deprivation, 64
- neuronal pathways, binding in REM sleep, 8–9
- neuronal restoration, 64–5
- neuropathies  
 restless legs syndrome in, 132, 135
- neurophysiology  
 changes in, 67  
 of sleep, 52–3, 79  
 testing, 134
- neuroplasticity, and sleep, 50
- neuropsychiatric disorders, 112, 382
- neuropsychological symptoms, 112–13, 153
- neuroregeneration, in sleep, 69
- neurotransmitter systems, 272, 308
- nicotine  
 ADHD and, 343  
 and sleep, 319, 320
- nicotinic cholinergic receptors, 305
- night awakenings  
 ADHD, 344, 349, 354  
 autism spectrum disorder, 376
- night eating syndrome (NES), 173
- night terrors, 80  
 age of patient, 42, 102  
 post-traumatic, 290
- nightmare disorder, 169–70
- nightmares, 80  
 effect on waking life, 87  
 in childhood, 358, 366  
 in narcolepsy, 86  
 post-traumatic, 80, 176
- night-time fears, 287, 365
- nitrazepam, 121
- nitric acid (NO), 26
- nocturnal awakenings  
 childhood depression, 359  
 dream recall, 85  
 multiple, 99, *see also* waking after sleep onset (WASO)
- nocturnal eating behaviors, 43  
 multiple, *see also* night eating syndrome (NES); sleep-related eating disorder (SRED)
- nocturnal frontal lobe seizures, 175
- nocturnal hypoxemia, 113–14, 118
- nocturnal immobility, 337
- nocturnal leg cramps, 141
- nocturnal leg pain, 131–2  
 multiple, *see also* restless legs syndrome (RLS)
- nocturnal motricity, 351
- nocturnal panic attacks, 176
- nocturnal penile tumescence (NPT), 39
- nocturnal polysomnogram, 163
- nocturnal sleep, hypnogram, 42
- non-24-hour sleep-wake syndrome, 189, 191, 192, 193, 195  
 multiple, *see also* non-entrained sleep phase disorder
- non-benzodiazepine receptor agonists, 308  
 side-effects, *see also* zopiclone
- non-benzodiazepines, 217–22  
 hypnotics, 121–2  
 side-effects, 221, *see also* triazolam; zolpidem
- non-entrained sleep phase disorder, 186
- non-ergot dopamine agonist, 137
- non-REM sleep *see* NREM sleep
- non-selective serotonergic antidepressants, 167
- noradrenaline (NA), 17
- noradrenergic antidepressants, 140
- noradrenergic neurons, 17, 23
- norepinephrine, 3–5
- norepinephrine reuptake inhibitors, 258
- normal sleep, monitoring, 39–40
- nose/mouth airflow, polysomnography, 40
- nosology, new developments, 393
- NREM sleep  
 AIM model, 6  
 arousal from, 162  
 classification, 18–19  
 cortical plasticity, 66–7  
 disorders of arousal, 160–1, 161–2  
 dreaming in, 80  
 electrophysiology, 37–8  
 functional neuroanatomy, 47–8  
 growth hormone release, 61  
 hyperarousal during, 209–10  
 in infancy, 42  
 N1 stage, 37  
 N2 stage, 37  
 N3 stage, 37–8  
 neural systems, 18–21  
 neuronal regeneration in, 64  
 night terrors, 80  
 orthodox sleep, 36  
 rCBF brain maps, 49  
 serotonin (5-HT), 16–17  
 sleep stage scoring, 41–2  
 slow-wave activity, 50  
 spindles, 67  
 NREM sleep parasomnias, 161–2, 178
- obesity  
 fat distribution pattern, 104  
 food addiction, 389  
 obstructive sleep apnea, 111, 120  
 and psychotic disorders, 274, 299  
 risk in sleep loss, 39  
 sleep-disordered breathing, 353
- obsessive-compulsive disorder (OCD), 286, 287  
 childhood anxiety disorders, 364  
 circadian rhythm sleep disorders, 195–6  
 REM sleep disturbances, 43
- obstructive sleep apnea (OSA), 111–12, 122  
 and ADHD, 120  
 and alcohol use, 122  
 and Alzheimer's disease, 334  
 and bipolar disorder, 274  
 and modafinil, 122  
 cognitive impairments, 112–15  
 cytokines and sleep, 119  
 depression and, 115–18, 119–20  
 diagnosis, 112  
 epileptiform activity, 175  
 excessive sleepiness, 100  
 historical reports, 111  
 history-taking, 104, 106  
 hypercarbia, 113–14  
 in children, 347, 372  
 in Down syndrome, 378  
 insomnia and, 205  
 n

## Index

- severe, 174  
 sleepwalking/sleep terrors and, 165  
 stroke risk, 335  
 symptoms, 111, 112, 116  
 treatment, 112, 117, 119–20  
 occipital cortex, 21–3  
 occupation *see* employment  
 OCD *see* obsessive-compulsive disorder (OCD)  
 olanzapine, 309  
   for insomnia, 224–5, 258  
   for post-traumatic stress disorder, 177, 287  
   risks in Alzheimer's disease, 333  
   side-effects, 135, 164  
 older patients  
   advanced sleep phase disorder, 331  
   parasomnias, 102–3  
   secondary sleep disorders, 331  
   sleep changes in, 330  
 Ondine's curse, 335  
 ontogeny, and sleep, 60, 68  
 opiates/opioids  
   effects on sleep, 46, 317  
   for restless legs syndrome, 138  
   withdrawal, 135, *see also* cocaine;  
   oxycodone; tramadol  
 oppositional defiant disorder (ODD), 343, 344, 346, 348  
 orexin (hypocretin)  
   dysfunction in narcolepsy, 149  
   feeding and satiety, 62  
   in ADHD, 353  
   in flip-flop switch, 21  
   new research, 387  
   vigilance state regulation, 18  
 orexin receptor antagonists, 388  
 organization of sleep, 41–7  
 oronasal airflow, 166  
 oropharyngeal abnormalities, 104  
 orthodox sleep, 36  
 OSA *see* obstructive sleep apnea (OSA)  
 oxidative processes, 63  
 oximetry, polysomnography, 168  
 oxycodone, 138  
  
 P50 suppression, 305  
 pain  
   insomnia and, 217, 228,  
     *see also* restless legs  
     syndrome (RLS)  
 pain relief  
   anticonvulsants, 226  
   opioid drugs, 317  
 panic attacks, 176, 289  
 panic disorder (PD), 289  
   as parasomnia, 176  
   diagnosis, 176, 286  
   insomnia, 176, 289  
  
 paradoxical insomnia, 210–11, 247  
 paradoxical sleep, 36  
 paralysis (sleep-related), 150  
   in history, 160, 170  
   recurrent isolated, 170  
 parasomnias, 160–1, 178  
   autism spectrum disorder, 376  
   differential diagnosis, 160, 168,  
     176–7  
   evaluation, 179  
   exploding head syndrome, 172  
   factitious, 177  
   historical view, 160–1  
   history-taking, 102–3  
   insomnia in, 205  
   polysomnography, 40  
   recurrent isolated sleep paralysis,  
     170  
   REM sleep, 166–70  
   sleep-related dissociative disorders,  
     170  
   sleep-related eating disorder, 172–4  
   sleep-related enuresis, 171  
   sleep-related groaning, 171  
   sleep-related hallucinations, 172  
   sleepwalking/sleep terrors, 162–4  
   symptoms, 104  
 parasthesias, 130–1  
 parasympathetic activation, 38  
 parent education, on sleep  
   disorders, 374  
 parkinsonism, dementia with Lewy  
   bodies, 335  
 Parkinson's disease (PD)  
   and bipolar disorder, 275  
   and REM sleep behavior disorder,  
     167  
   diagnostic features, 336  
   history-taking, 104  
   pharmacotherapy, 137, 138,  
     169, 333  
   polysomnography, 332  
   restless legs syndrome treatment  
     compared, 137  
   secondary circadian rhythm sleep  
     disorder, 186–7  
   sleep disturbance, 334  
 Parkinson's disease dementia  
   (PDD), 336  
 Parkinson's plus syndromes, 334  
 paroxetine, 121, 140, 164, 293  
 paroxysmal arousals, 40  
 partial sleep deprivation, 252–3  
 pathophysiologic mechanisms, 389  
 patient counseling  
   in excessive sleepiness, 156,  
     *see also* sleep habits/hygiene,  
     advice  
 patient non-compliance, 242–3, 307  
  
 PD *see* Parkinson's disease (PD)  
 pediatric bipolar disorder (BPD)  
   ADHD co-morbidity, 343, 345  
   mania, 363  
   sleep and, 358, 363  
 pediatrics *see* childhood  
 pedunculopontine tegmental (PPT)  
   neurons, 15, 16, 23, 24–5  
 pedunculopontine tegmental  
   nuclei, 15  
 penile tumescence, nocturnal, 39  
 performance impairment  
   chronic insomnia, 233  
   in obstructive sleep apnea, 112–13,  
     114–15  
 pergolide, 137  
 perifornical region, 18  
 period 3 gene polymorphisms, 273  
 period 3 genes, 189, 193  
 period gene products (PER1/2), 28  
 periodic limb movement disorder  
   (PLMD), 130  
   ADHD and, 347  
   diagnosis, 130–2  
   dreams and, 86  
   epidemiology, 132–4  
   genetics, new research, 390  
   in panic disorder, 332  
   polysomnography, 40, 332  
   treatment, 136–8  
 periodic limb movements during  
   wakefulness (PLMW),  
   130–1  
 periodic limb movements of sleep  
   (PLMS), 130–1  
   ADHD, 346, 347, 351  
   alcohol abuse and, 316

## Index

- pharmacotherapy (cont.)  
 in dementia with insomnia, 340  
 new treatments, 391  
 panic disorder, 338  
 pediatric depression, 359, 366  
 psychiatric disorders, 354, 388  
 psychotic disorders and sleep  
 disturbance, 305  
 research study caveats, 388  
 substance-related insomnia, 319  
 with cognitive behavioral therapy  
 for insomnia, 235, 241–2  
 phase advance hypothesis, 257, 348  
 phase advance therapy, 259, 271  
 phasic (episodic) components,  
 REM sleep, 38  
 phasic muscle activity, 40  
 phenomenology, in dreams, 82–3  
 phenytoin, 44  
 phobic disorders, 287  
 phototherapy, 241  
 physical deformity, pediatric  
 insomnia, 373  
 physical examination  
 history-taking, 104–6  
 in dementia with insomnia, 340  
 physiological apnea process, 85  
 physiological arousal, 209  
 physiological changes  
 discovery of, 5  
 in sleep, 38–9, 107  
 physiological parameters, in  
 dreaming, 80  
 pindolol, 271  
 pineal gland, 187–8  
 Pittsburgh Sleep Quality Index (PSQI),  
 205–6, 317  
 PLMD *see* periodic limb movement  
 disorder (PLMD)  
 PLMS *see* periodic limb movements of  
 sleep (PLMS)  
 polysomnography (PSG), 40, 107, 205  
 ADHD, 348, 349, 350, 352, 353  
 anxiety disorders, 287  
 autism spectrum disorder, 376  
 clinical research, 40  
 dementia with insomnia, 340  
 depression, 361  
 dissociative disorders, 170  
 euthymic bipolar subjects, 272  
 excessive sleepiness, 107  
 in children, 361, 376  
 in multiple sleep latency test,  
 147–8  
 mania, 267  
 obsessive-compulsive disorder, 288  
 obstructive sleep apnea, 165,  
 166, 175  
 panic disorder, 332, 338  
 periodic limb movement disorder,  
 130–1, 332  
 periodic limb movements of  
 sleep, 133  
 psychiatric disorders, 42–3, 300  
 REM sleep behavior disorder, 167,  
 168, 336  
 restless legs syndrome, 130–1  
 schizophrenia, 304  
 sleep terrors, 162, 163  
 sleepwalking, 162, 163  
 smoking and, 320  
 substance misuse, 314, 317, 319  
 pons, 2–4, 23, 48  
 pontine sublaterodorsal nucleus  
 activation, 23–4  
 pontine tegmentum, 21–3, 336  
 ponto-geniculo-occipital (PGO)  
 waves, 6, 21–3, 49  
 positive airway pressure (PAP),  
 40, 274  
 positive myoclonus, 37  
 positron emission tomography (PET),  
 47, 51–2, 209  
 posterior hypothalamus, 17  
 post-partum psychosis, 269  
 post-traumatic parasomnia, 170  
 post-traumatic re-enactment  
 dreams, 80  
 post-traumatic stress disorder  
 (PTSD), 177  
 childhood anxiety disorders, 363  
 diagnosis, 176–7, 290  
 sleep disturbance, 176–7, 290  
 bidirectional model, 388  
 REM sleep, 43  
 treatment, 177, 292  
 power spectral analysis (PSA),  
 249–50  
 PPT *see* pedunculopontine tegmental  
 (PPT) neurons  
 Prader-Willi syndrome (PWS), 379  
 pramipexole  
 panic disorder, 337  
 periodic limb movement disorder,  
 137–8  
 REM sleep behavior disorder, 169  
 restless legs syndrome, 137–8, 275  
 prazosin, 170, 177, 293  
 precipitating factors, in insomnia,  
 96–7, 237  
 prefrontal model, in obstructive sleep  
 apnea, 113–14  
 pregabalin, 226, 292  
 preoptic nuclei, 20  
 prevention strategies, mental  
 illness, 388  
 priapism, trazodone-induced,  
 224, 258  
 primacy of sleep, 61  
 primary circadian rhythm sleep  
 disorders, 186–90, 191  
 primary insomnia, 236–7, 248  
 classification, 204  
 new treatment, 392  
 primary restless legs syndrome  
*see* idiopathic restless legs  
 syndrome  
 primary sleep disorders, 147–8, 191  
 bipolar disorder and, 274–5  
 in ADHD, 346, 350  
 psychotic disorders and, 298, 305  
 prion diseases, 340  
 process C, sleep regulation, 26–9  
 process S, sleep regulation, 25–6  
 professional issues, in sleep  
 medicine, 393  
 progress graphs, client motivation, 243  
 progressive supranuclear palsy (PSP), 338  
 prolactin, 39, 61  
 prostaglandin (PGD2), 26  
 protein biogenesis, 64  
 protoconsciousness, 6, 8–9  
 PSG *see* polysomnography (PSG)  
 psychiatric assessment  
 parasomnias, 178–9  
 sleepwalking and, 163–4  
 psychiatric developmental disorders,  
 371, 380  
 psychiatric disorders  
 ADHD co-morbidity, 343, 344  
 circadian rhythm sleep disorders  
 and, 192–7  
 differential diagnosis, 112, 176–7  
 fatigue defined, 99–100  
 genetics, 390  
 history-taking, 95–6, 103  
 hypersomnia, 155–6  
 insomnia as risk factor, 234  
 insomnia in, 205, 208, 236–7  
 prevention, 388  
 treatment, 226–8, 236  
 neurobiology of, 52–3  
 pediatric, 358  
 REM sleep behavior disorder,  
 168  
 sleep abnormalities, 42–3, 95–6  
 sleep-related eating disorder, 173  
 thermoregulation abnormalities, 39  
 treatment,

## Index

- psychological problems  
 childhood insomnia, 372, 378  
 dream deprivation, 2  
 in insomniacs, 97  
 psychomotor deficits, 101, 114–15, 148  
 psychomotor vigilance task, 113  
 psychopathology, 84–5, 160  
 psychophysiology  
 insomnia, 247  
 measures of arousal, 209  
 psychosis, drug-induced, 138  
 psychosis-like quality, dreaming, 4  
 psychosocial stressors, sleep deficit,  
 168, 208, 306  
 psychotherapy, 87, 276  
 psychotic disorders, 306  
 classification, 307  
 diagnosis, 300, 307  
 medication withdrawal, 304  
 polysomnography, 300  
 poor sleep hygiene, 299  
 REM abnormalities in, 305  
 sleep deficits in, 298  
 sleep disorder co-morbidity, 298  
 sleep disturbance in, 298, 299,  
 308, 309  
 sleep interactions with, 305  
 slow-wave sleep in, 303  
 psychotropic drugs, 164, 167, 173, 304  
 slow-wave sleep in, *see also* selective  
 serotonin reuptake inhibitors  
 (SSRIs)  
 PTSD *see* post-traumatic stress  
 disorder (PTSD)  
 public health issue, insomnia as, 211–12  
 PWS (Prader-Willi syndrome), 379
- quality of life (QoL), 138, 211, 305, 330  
 quazepam, 217, 318  
 questionnaires  
 ADHD sleep disorders, 350, 352  
 excessive daytime sleepiness, 147  
 quetiapine, 224–5  
 bipolar insomnia, 277  
 depression-related insomnia, 258  
 parasomnias, 164  
 post-traumatic stress disorder,  
 177, 293  
 side-effects, 135, 333  
 substance-related insomnia, 323  
 quiet sleep, in infancy, 42
- radiculopathies, 135  
 ramelteon, 222, 277, 318  
 rapid eye movement sleep *see* REM sleep  
 RBD *see* REM sleep behavior  
 disorder (RBD)  
 rCBF *see* regional cerebral blood  
 flow (rCBF)
- rebound effect, ADHD medication,  
 345, 352  
 reboxetine, 164  
 reciprocal interaction model, 3,  
 4–5, 24–5  
 recurrent hypersomnias, 153–4  
 recurrent isolated sleep paralysis, 170  
 regeneration, neuronal, 64  
 regional cerebral blood flow (rCBF), 49  
 in insomnia, 209–10  
 neuroplasticity and sleep, 50  
 NREM sleep, 47  
 REM sleep, 48–50  
 relaxation training, 164–5, 241, 291  
 REM density, in depression,  
 248–9, 255  
 adolescents, 361  
 children, 360, 361  
 REM latency  
 in depression, 251, 255  
 adolescents, 361  
 children, 360  
 in major depressive disorder,  
 248–9, 256  
 in schizophrenia, 43, 301  
 REM sleep, 3  
 AIM model, 6  
 and immaturity, 8, 42  
 binding problem, 8–9  
 depressogenic theory, 256  
 deprivation, 64, 253  
 discovery, 2, 9–10  
 dreaming, 2  
 dreaming in, 6, 7, 79, 80  
 dreams, 80, 88  
 electrophysiology, 2–4, 37  
 functions of, 87–8  
 in ADHD, 350  
 in anxiety disorders, in children, 364  
 in major depressive disorders, 43  
 in narcolepsy, 86  
 muscle atonia in, 336, 337  
 neuroimaging, 48–50  
 nightmares, 80  
 panic disorder, 337  
 paradoxical sleep, 36  
 parasomnias, 161, 166–70, 178  
 post-traumatic stress disorder, 290  
 Prader-Willi syndrome, 379  
 psychiatric disorders, 42–3  
 psychotic disorders, 43, 301, 305  
 rCBF brain maps, 49  
 reciprocal interaction model, 24–5  
 serotonin (5-HT), 16–17  
 sleep stage scoring, 41–2, 147–8  
 substance abuse, 314, 317, 319  
 synaptic plasticity, 66  
 tonic (persistent) components, 38  
 vigilance state regulation, 21–5
- REM sleep behavior disorder (RBD),  
 166–8, 169  
 acute transient, 167  
 dementia with Lewy bodies, 335  
 diagnosis, 167, 393  
 in panic disorder, 337, 338  
 multiple system atrophy, 338  
 muscle atonia in, 337  
 polysomnography, 168  
 time of night, 102  
 treatment, 169  
 REM-active neurons, inhibition, 23  
 REM-off neurons, 25  
 REM-on neurons, 23, 24  
 renal disease, 135  
 repetitive transcranial magnetic  
 stimulation (rTMS), 50  
 reproductive system, 39  
 research  
 CPAP effects on mood, 118  
 dream content, 83  
 modern developments, 36  
 pharmacotherapy, 388  
 reserpine, 169  
 respiratory depression, 121–2  
 respiratory effort  
 polysomnography, 40,  
*see also* obstructive sleep  
 apnea (OSA)  
 respiratory inductive  
 plethysmography (RIP), 40  
 respiratory system, during sleep, 39  
 respite care, for caregivers, 334  
 rest-induced pain, 130–1  
 restless legs syndrome (RLS), 130–1  
 ADHD, 346, 350, 351  
 age distribution, 132  
 alcohol abuse, 316  
 diagnosis, 106–7, 130–2, 133, 134  
 criteria, 131–2, 393  
 symptoms, 105, 130–1  
 dopaminergic system in, 134  
 drug-induced, 135–6, 139–40  
 epidemiology, 132–4, 136  
 genetics in, 134, 390  
 idiopathic, 132, 134

## Index

- reticular activating system (RAS), 15  
 reticular formation (RF), 15, 23  
 reticular nucleus (RET), 19  
 retinohypothalamic pathway, 28  
 retinoid-related orphan nuclear  
   receptor alpha (Rora), 28  
 Rett syndrome, 381  
 Rev-Erb $\alpha$  gene polymorphisms, 273–4  
 Rev-Erb $\alpha$  orphan nuclear receptor, 28  
 reverse learning theory, 88  
 reward processing, 389  
 rheumatoid arthritis/rheumatological  
   conditions  
     hypersomnia, 154  
     insomnia, 217, 228  
     nocturnal leg pain, 131  
     secondary restless legs syndrome, 135  
 risperidol, 196  
 risperidone, 135, 333  
 rivastigmine, 333  
 RLS *see* restless legs syndrome (RLS)  
 ropinirole  
   periodic limb movement disorder,  
     137–8, 336, 337  
   restless legs syndrome, 137–8, 275  
   side-effects, 338  
 rotigotine, 137–8
- safety issues, insufficient sleep, 148  
 Sanfilippo syndrome, 378  
 satiety hormones, 39  
 scales and inventories, 106  
 schizoaffective disorders  
   diagnostic criteria, 300  
   polysomnography, 300  
   sleep disorders and, 195, 298  
   violent behavior, 306  
 schizophrenia  
   diagnostic criteria, 298, 300  
   hallucinations, 84  
   polysomnography, 300  
   poor sleep hygiene, 299, 300  
   primary sleep disorders and, 298  
   prodromal sleep disturbance, 304  
   REM sleep in, 301  
   risk factors, 304  
   sleep disturbances, 43, 228,  
     301, 304  
   sleep spindle activity, 40, 390  
   slow-wave sleep abnormalities, 303  
   synaptic pruning, in adolescence, 42  
   treatment, side-effects, 121, 196  
 SD *see* sleep deprivation (SD)  
 SDB *see* sleep-related breathing  
   disorders (SRBDs)  
 seasonal affective disorder (SAD),  
   193, 392  
 secondary circadian rhythm sleep  
   disorder, 186–7
- secondary insomnia, 204, 236–7  
 secondary restless legs syndrome,  
   135, 136  
 secondary sleep disorders, 331  
 sedative antidepressants, 139, 308  
   bipolar insomnia, 277  
   major depressive disorder, 227  
   substance-related insomnia, 323,  
     *see also* antihistamines;  
     antipsychotics  
 sedative-hypnotics, 121–2, 164, 258–9  
   *see also* alcohol; antihistamines;  
   benzodiazepines  
 sedatives, 120  
   pediatric insomnia, 366, 373  
   psychiatric disorders, 155–6, 269–70  
   with SSRIs, 366  
     *see also* lorazepam  
 seizure-related paroxysmal arousals, 40  
 seizures  
   alcohol abuse risk, 322  
   in sleep restriction therapy, 238  
   nocturnal, 175  
 selective extrasynaptic GABA<sub>A</sub>  
   receptor antagonists  
   (SEGAs), 46  
 selective serotonin reuptake inhibitors  
   (SSRIs), 44, 121, 258  
   for children, 359, 366  
   in anxiety disorders, 292, 293  
   insomnia treatment in  
     depression, 258  
   side-effects, 121, 167,  
     *see also* citalopram;  
     clomipramine; escitalopram,  
     fluoxetine; fluvoxamine;  
     paroxetine; sertraline  
   bruxism exacerbation, 141  
   restless legs syndrome, 135–6, 140  
   sleep disturbances, 196, 345, 352  
 self-hypnosis, 164–5  
 sensory deficits, pediatric insomnia, 373  
 sensory perceptions, in dreams,  
   82, 83  
 separation anxiety disorder (SAD),  
   286, 290  
 serotonergic system, 23, 118  
 serotonin, 3–5, 121  
 serotonin 5-HT<sub>1</sub>, 16–17  
 serotonin 5-HT<sub>1A</sub>-beta adrenoceptor  
   blocking agent, 271  
 serotonin 5-HT<sub>2</sub> receptor antagonists,  
   177, 308, 391  
 serotonin 5-HT<sub>2A</sub> receptor, T variant,  
   272  
 serotonin 5-HTTLPR transporter,  
   272, 390  
 serotonin neurotransmission  
   deficit, 256
- serotonin precursor, 121  
 serotonin-norepinephrine reuptake  
   inhibitors (SNRIs), 44,  
   151, 292  
   side-effect, 135–6, 140,  
     *see also* duloxetine, venlafaxine  
 sertraline, 140, 293  
 serum laboratory tests, 106–7  
 sexsomnia, 174  
 sexual abuse, 291  
 sexual behavior, confusional  
   arousal, 162  
 sexual dreams, 81  
 shift work  
   history-taking, 104  
   insufficient sleep, 148  
   sleep disturbances, 13, 96, 97, 186  
   treatment, 149, 192  
 short sleep duration, childhood  
   depression, 358  
 short-term memory, in obstructive  
   sleep apnea, 113  
 single nucleotide polymorphisms  
   (SNPs), in movement  
   disorders, 390  
 single photon emission computed  
   tomography (SPECT), 47,  
   162, 209–10  
 sleep, 36–8  
   cerebral cortex deafferentation, 15  
   homeost

## Index

- sleep deprivation (SD)  
 and somnogens, 25, 26  
 antidepressant action, 392  
 as therapy, 238, 240, 271–2, 276  
 confusional arousal, 162  
 endocrine effects, 39, 61  
 excessive sleepiness, 149–50  
 fatality in, 61  
 in delayed sleep phase disorder, 188–9  
 in depression, 252–3  
 insomnia and, 203  
 neuroimaging studies, 50–2  
 NREM sleep, 37  
 older patients, 330  
 panic disorder, 337  
 Prader-Willi syndrome, 379  
 schizophrenia, 306  
 studies on, 64, 267–8  
 total, 252, *see also* excessive daytime sleepiness (EDS)
- sleep diaries/sleep logs, 100, 207, 212  
 dream diaries, 81, 82  
 excessive sleepiness evaluation, 147  
 in cognitive therapy for insomnia, 239–40  
 insomnia, 99, 206  
 sleep–wake cycle monitoring, 190–1
- sleep disorder scales and inventories, 106
- sleep disordered breathing (SDB)  
*see* sleep-related breathing disorders (SRBDs)
- sleep disorders, 205, 236  
 ADHD and, 120  
 and dreams, 85–6  
 defining symptoms, 105  
 depression and, 358–63  
 genetics, 390  
 history-taking, 95–6  
 in childhood, 42, 358–63, 372, 374  
 in psychiatric illness, 43  
 key parameters, 95  
 polysomnography, 40  
 psychotic co-morbidities, 306  
 screening for, 147–8  
 slow-wave sleep-related, 42  
 symptoms, 104, 105  
 training and education needs, 393
- sleep disturbance  
 ADHD and, 120, 350  
 anxiety disorders, 291, 293  
 bipolar disorder, 270–1, 277–8, 363  
 cancer, hypersomnia, 155  
 cognitive deficits, 306  
 depressive disorders, 270–1  
 endocrine system effects, 39  
 in childhood  
 mood disorders, 361, 363  
 restless legs syndrome, 133–4  
 in depression, 253–7, 361  
 mania prognosis, 269  
 mood disorders, 247–51  
 parasomnias and, 160–1  
 post-traumatic stress disorder, 176–7  
 psychiatric disorders, 42–3, 389  
 psychotic disorders, 300, 307, 309  
 schizophrenia, 301, 304, 306  
 public health issue, 13  
 restless legs syndrome, 130–1, 133–4, 138, *see also* insomnia; subjective sleep disturbance
- sleep efficiency (SE), 42  
 antidepressants and, 223  
 antipsychotics and, 46  
 in ADHD, 349  
 in psychotic disorders, 300, 301  
 marijuana use, 317
- sleep fragmentation, 146, 249  
 chronic, endocrine system in, 39  
 cognitive impairments by, 113–14  
 in ADHD, 349  
 in anxiety disorders, 43  
 in congestive heart failure, 154–5  
 in depressive conditions, 118, 247–51, 253–5  
 in obstructive sleep apnea, 113–14, 118  
 in panic disorder, 337  
 in psychiatric disorders, 42–3  
 nicotine and, 320
- sleep functions, 59–61, 68–70  
 cognitive theories, 65–8  
 neural theories, 63–5  
 somatic theories, 61–3  
 unifying theory of, 61
- sleep habits/hygiene, 84  
 advice, 148–9  
 Alzheimer's disease, 333  
 cognitive behavior therapy, 238–9, 240, 291  
 autism spectrum disorder, 376  
 in sleep disruption, 99  
 mood and anxiety disorders, 291, 365  
 perpetuating insomnia, 210  
 psychotic disorders, 298, 299  
 smoking status and, 320
- sleep inertia, in idiopathic hypersomnia, 152
- sleep logs *see* sleep diaries/sleep logs
- sleep medicine, 5  
 departments, 5  
 development, 2–6, 9–10  
 recent growth of, 394  
 significance, xiii–xiv  
 training programs, 393
- sleep medicine consultations, 107  
 training programs, *see also* history-taking
- sleep medicine departments, 393
- sleep monitoring tools, 39–41  
 hypnogram, 42, *see also* electroencephalography (EEG); polysomnography (PSG)
- sleep need decrease, in mania, 266–7
- sleep onset dreams, 80
- sleep onset hallucinations, 37
- sleep onset latency (SOL)  
 childhood mood disorders, 358, 359, 362, 364  
 in ADHD, 345, 349  
 in anxiety disorders, 43, 362  
 in insomnia, 99  
 melatonin receptor agonists in, 222  
 non-benzodiazepines for, 221  
 psychiatric disorders, 42–3  
 psychotic disorders, 301, 305  
 sleep architecture variables, 42  
 substance use, 314, 319, 321  
 tricyclic antidepressants in, 223, *see also* multiple sleep latency test (MSLT)
- sleep patterns, history-taking, 99
- sleep reduction  
 final common pathway model, 268  
 in mania, 268–9  
 mania caused by, 267–8
- sleep research *see* research
- sleep restriction therapy, 238, 240, 271–2, 276
- sleep spindles, 18, 37, 47–8  
 EEG monitoring, 39  
 in schizophrenia, 40, 304, 390  
 synaptic plasticity, 67  
 vigilance state regulation, 19
- sleep stages, 36–8, 41–2  
 electrophysiological criteria, 36–8  
 functional neuroanatomy, 47–50  
 physiological changes, 38–9  
 regional cerebral blood flow, 49
- sleep terrors (STs), 160, 162–4, 165,

## Index

- sleep-related breathing disorders (SRBDs), 111–12, 122, 393  
 ADHD and, 348, 349, 351, 353  
 alcohol dependency and, 316  
 anxiety in, 120  
 depression in, 115–18  
 in craniofacial syndromes, 381  
 polysomnography, 40, 107  
 post-traumatic stress disorder, 290  
 psychiatric medications and, 120–2  
 psychotic disorders and, 299
- sleep-related eating disorder (SRED), 43, 161, 172–4
- sleep-related movement disorders (SRMDs), 130, 140, 141  
 psychotic disorders and,  
*see also* periodic limb movement disorder (PLMD); restless legs syndrome (RLS)
- sleep-related respiratory disorders (SRRDs) *see* sleep-related breathing disorders (SRBDs)
- sleep-related rhythmic movement disorder, 140
- sleep-state misperception insomnia, 210–11, 247
- sleep–wake activity inventory, 147
- sleep–wake cycle  
 irregular, 186, 190  
 monitoring, 190–1  
 non-24-hour sleep–wake syndrome, 186  
 personality disorders and, 195  
 pontine tegmental neurons, 22
- sleep–wake cycle disruption, 42–3, 190  
 Alzheimer's disease, 332  
 fetal alcohol spectrum disorder, 380  
 medication-induced, 196, 197  
 substance abuse effects, 314  
 tuberous sclerosis, 380,  
*see also* advanced sleep phase disorder; circadian rhythm sleep disorders (CRSDs); delayed sleep phase disorder
- sleep–wake state misalignment, in parasomnias, 160–1
- sleepiness  
 fatigue differentiated, 203  
 sleep fragmentation, 146  
 sleep restriction therapy, 238,  
*see also* daytime sleepiness
- sleepwalking (SW), 160, 162–4, 165–6  
 age of patient, 102  
 assessments, 179  
 treatment, 164–5
- slow-wave activity (SWA)  
 evolutionary sleep spandrel, 60  
 neuroimaging, 47–8, 50  
 synaptic plasticity, 50, 67
- slow-wave sleep (SWS)  
 confusional arousals, 161–2  
 deficits, 256, 306  
   in major depressive disorders, 43  
   in schizophrenia, 43, 304  
 depression and, 250, 255, 256  
 in adolescence, 42  
 in childhood, 42  
 in delayed sleep phase disorder, 189  
 in psychotic disorders, 303, 305  
 major depressive disorder, 248, 249  
 medication effects, 308, 391  
 NREM classification, 18–19, 37  
 polysomnography, 317  
 substance use, 314, 317, 320, 321  
 thermoregulation in, 39,  
*see also* NREM sleep, N3 stage
- Smith-Magenis syndrome, 381
- smoking *see* nicotine
- SNRIs *see* serotonin-norepinephrine reuptake inhibitors (SNRIs)
- social life  
 history-taking, 104  
 impairment, 97, 193, 233  
 insomnia risk, 206–8  
 restless legs syndrome and co-morbidities, 138
- social phobia (SOC), 287
- societal expectations, personality disorders and, 195
- sodium oxybate, 150–1
- sodium-mediated spikes, EEG activity, 19
- SOI *see* sleep-onset insomnia (SOI), in ADHD
- soluble tumor necrosis receptor 1 (sTNF-R1), 118
- somatic theories, sleep function, 61–3
- somnambulism, 42, 160  
 restless legs syndrome and co-morbidities,  
*see also* sleepwalking
- somnogens, 25–6
- specific phobias, 287
- restless legs syndrome and co-morbidities,  
*see also* generalized anxiety disorder (GAD); separation anxiety disorder (SAD)
- SPECT (single photon emission computed tomography), 47, 162, 209–10
- Spielman model, 237
- SRBDs *see* sleep-related breathing disorders (SRBDs)
- SRED *see* sleep-related eating disorder (SRED)
- SSRIs *see* selective serotonin reuptake inhibitors (SSRIs)
- ST *see* sleep terrors (STs)
- Stanford sleepiness scale (SSS), 41, 147
- stimulant drugs  
 effects on sleep, 352  
 for ADHD, 343, 345, 352  
 for hypersomnia, 153, 275  
 for narcolepsy, 151  
 parasomnias and, 164  
 side-effects, 151,  
*see also* methylphenidate
- stimulus control therapy, 238, 240
- STOP-bang scoring model, 106
- stress (psychosocial)  
 and sleepwalking, 162  
 dream content and, 83, 84  
 insomnia and, 17  
 REM sleep behavior disorder and, 168  
 sleep deprivation studies, 64
- stridor, inspiratory, 338
- stroke patients  
 breathing failure, 335  
 Broca's area aphasia, 50  
 vascular dementia, 334, 335
- stupor, idiopathic recurring, 153–4
- subjective sleep disturbance, 298
- substance abuse, 389  
 ADHD and, 343, 345  
 effects on sleep and wakefulness, 325  
 sleep disturbance, 43  
 withdrawal problems  
*see also* alcohol abuse-induced sleep disorders; opiates/opioids
- alcohol, 318  
 anticonvulsants, 322  
 cannabis use, 316  
 cocaine, 319  
 opioid drugs, 317
- substance use  
 CNS sedating substances, 314  
 diagnostic criteria, 314  
 history-taking, 103  
 withdrawal problems, 320, 321, 322
- substance use disorders, 314, 322
- suicidal behavior, 155, 300, 387
- sundowning, 33

## Index

- T variant on 5-HT<sub>2A</sub> receptor, 272  
 tauopathies, 338, 339  
 TCAs *see* tricyclic antidepressants (TCAs)  
 teeth grinding (bruxism), 141  
 temazepam, 217, 258  
   abuse and dependence, 318  
   with cognitive therapy, 242  
 temperature circadian rhythm, 191  
 temporal cortex activation, 49–50, 362  
 tetracyclic antidepressants, 135–6  
 thalamic-reticular dysfunction, 304  
 thalamocortical interactions, 67  
   dysfunction, 304  
 thalamocortical neurons, 19  
 thalamocortical spindles, 67  
 thalamus, reticular nucleus of, 19  
 thermoregulation, during sleep, 39, 60  
 theta waves, 14–15, 18, 23  
 thinking disturbance, 305  
 threat simulation theory, in  
   dreaming, 88  
 thyroid hormone levels, in sleep  
   deprivation, 61  
 thyroid-stimulating hormone (TSH),  
   release timing, 39  
 tiagabine, 226  
   for bipolar insomnia, 277  
   for post-traumatic disorder  
     nightmares, 177  
   for substance-related insomnia, 322  
   in anxiety disorders, 292  
 time of night  
   dream content and, 84  
   parasomnias, 102–3  
 tiredness, 148  
 TMN (tuberomammillary nucleus), 17  
 TMS (transcranial magnetic  
   stimulation), 50, 391  
 tobacco *see* nicotine  
 tonic muscle activity, 40  
 topiramate, 164, 174, 177  
 total sleep deprivation (TSD), 252  
 total sleep time (TST)  
   in psychotic disorders, 301, 333  
   substance use and, 316, 317, 320  
 Tourette syndrome, 343, 345, 382, 390  
 traffic accidents, 113  
   sleep loss and, 148, 211  
   sleepiness in, 37, 101–2, 156  
   vigilance deficits, 113  
 tramadol, 138  
 transcranial magnetic stimulation  
   (TMS), 50, 391  
 transplant patients, secondary restless  
   legs syndrome, 135  
 trazodone, 223–4  
   abuse and dependence, 318  
   for ADHD, 352  
   for bipolar insomnia, 277  
   mood disorders, 227, 258, 366  
   side-effects, 224  
   sleepwalking/sleep terrors  
     therapy, 164  
   substance-related insomnia,  
     227, 321  
 treatment compliance, 242–3, 307  
 triazolam, 121, 217, 228  
 tricyclic antidepressants (TCAs), 44  
   as antiepileptic agents, 151  
   drug-induced parasomnias, 169  
   for insomnia, 223, 257  
   side-effects, 223  
   sleep quality, 223,  
     *see also* trimipramine  
 trimipramine, 223  
 tuberomammillary nucleus (TMN), 17  
 tuberous sclerosis, 380  
 tumor necrosis factor (TNF),  
   62, 118  
 two-process model, sleep regulation,  
   13, 25–9  
  
 unifying theory, of sleep function, 61  
 upper airway obstruction, 378  
 upper airway resistance syndrome  
   (UARS), 116  
 U-R-G-E, in restless legs  
   syndrome, 130  
 uridine, 63  
  
 valproic acid, 138, 164, 275  
 vascular dementia, 334, 335  
 venlafaxine, 135–6, 140, 258  
 ventral arousal pathway, 15  
 ventrolateral preoptic nucleus  
   (VLPO), 20–1  
 verbal learning, 114  
 vertical supranuclear gaze palsy, 338  
 vigilance state regulation, 13–14, 29  
   deficits, 112, 113  
   neural systems, 10, 14–25  
   sleep regulation, 25–9  
 violent behavior  
   confusional arousal, 162  
   schizoaffective disorder, 306  
   sleepwalking/sleep terrors, 163, 164  
 viral infections, 62, 152  
 visual hallucinations, 172  
 visual impairment, pediatric  
   insomnia, 373  
 visual system  
   development of, 8, 66–7  
   in circadian rhythmicity, 28  
   in dreaming, 9, 82  
 vocal cord abductor paralysis, 338  
  
 wake REM-on neurons, 23, 24  
 wake-on/REM-off neurons, 23  
 wake-promoting medication, 122,  
   242, 258  
 wakefulness  
   acetylcholine in, 15–16  
   alertness values, 41  
   electrophysiological parameters, 37,  
     38, 40  
   flip-flop hypothesis, 13  
   hypoarousal during, 209–10  
   maintenance of wakefulness test, 41,  
     107, 148  
   neural systems, 14–18  
   rCBF brain maps, 49  
   staying in bed, 237  
   substance abuse and, 325  
 wakefulness–sleep transitions, 20–1  
 waking activities, neuroplasticity and  
   sleep, 50  
 waking after sleep onset (WASO),  
   361  
 waking consciousness  
   dreaming and, 9  
   unity in, 8–9  
 waking state, AIM model, 6  
 waking-life  
   dreaming and, 83–4  
   continuity hypothesis, 84  
   effect of dreams, 86–7, 88  
 war veterans, 177  
 weight gain  
   antipsychotic drugs, 121  
   sleep-related eating disorder, 173  
 Williams syndrome, 381  
 work patterns, sleep disturbance, 13  
 work performance, impairment, 233  
 working memory, sleep deprivation  
   and, 50–1  
  
 zaleplon, 217